# CART-EGFRvIII + Pembrolizumab in GBM

> **NCT03726515** · PHASE1 · COMPLETED · sponsor: **University of Pennsylvania** · enrollment: 7 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **BIOLOGICAL:** CART-EGFRvIII T cells
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03726515
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-11
- **Primary completion:** 2021-02-27
- **Final completion:** 2021-02-27
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03726515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03726515, "CART-EGFRvIII + Pembrolizumab in GBM". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03726515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*